focus -WSS

focus

author：comprehensive 2025-09-02 08:11:05 - browse：638

A person picking up medication at a drive through pharmacy window – biotech and pharma coverage from STAT — Adobe

On Tuesday morning, the Department of Health and Human Services unveiled its long-awaited list of the 10 medicines that will be subject to price negotiation in 2026 under the Inflation Reduction Act.

This will mark the first time that Medicare, the government program for paying for health care for older Americans, will have any ability to use its vast size to negotiate for lower prices. It’s not yet clear how big the discounts on these 10 drugs will be, or even if the law will hold up to multiple legal challenges from the pharmaceutical industry. It’s also not clear, as critics from the drug industry have noted, whether any savings to the government will be passed on to consumers.

Still, the naming of 10 medicines is a milestone, and a point to start appraising the impact of the law. The landscape here is complicated. No one really knows how the IRA’s price negotiation process will play out over the short and long term, and many companies who had products named were spared in other ways, with products many industry watchers expected to see on the list absent. Here is STAT’s assessment of who has won and lost.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： What will Novo Nordisk's VC do with its influx of cash?

WSS

Health insurers' Q3 question: how much care are people getting?

Biden administration plans revamp of organ transplant system

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

Will an HIV vaccine ever be a reality?

Living organ donors deserve priority status for transplants

European officials brace for rough respiratory virus season

hotspot

focus

entertainment

In age of alternative facts, a scholarly course on calling out crap

Bispecific antibodies are next new thing in cancer immunotherapy

As demand for Covid shots wanes, Moderna seeks its next success

WHO recommends second malaria vaccine

After affirmative action ruling, medical educators look to 'holistic review'

The biotech scorecard for Q4: 16 stock

New air purifier tech could be key to improving indoor air quality

Reanimated hearts work just as well for transplants, study finds

United colonoscopy coverage change 'may cost lives,' doctors say

Senate panel passes drug pricing bills, but drops one PBM reform

Wikipedia

Patients, doctors are clashing about side effects of hormonal birth control

Can medical device makers keep up in the race to treat obesity?

Reanimated hearts work just as well for transplants, study finds

Reanimated hearts work just as well for transplants, study finds

Health insurers' Q3 question: how much care are people getting?

A public health expert passes on football's full body collisions for youths

hotspot

explore

Wikipedia

focus